BRCA1 Gene Mutation Clinical Trial
Official title:
Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT01907438 -
Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Withdrawn |
NCT02309632 -
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
|
N/A | |
Active, not recruiting |
NCT01009788 -
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
|
Phase 2 | |
Completed |
NCT01251874 -
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT02197000 -
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers
|
N/A | |
Recruiting |
NCT03428802 -
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
|
Phase 2 | |
Completed |
NCT03377556 -
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04294927 -
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
|
N/A | |
Active, not recruiting |
NCT03943173 -
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
|
Early Phase 1 | |
Active, not recruiting |
NCT02953457 -
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
|
Phase 2 | |
Completed |
NCT01975363 -
Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer
|
N/A | |
Completed |
NCT01948609 -
Prospective Research of Outcomes After Salpingo-oophorectomy
|
||
Active, not recruiting |
NCT03552471 -
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT02225015 -
Cancer Prevention in Women With a BRCA Mutation
|
Phase 1 | |
Active, not recruiting |
NCT02321228 -
Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers
|
N/A | |
Recruiting |
NCT04030559 -
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
|
Phase 2 | |
Terminated |
NCT01905592 -
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
|
Phase 3 | |
Recruiting |
NCT02474264 -
The Link Between BRCA Mutation and Endothelial Function
|
N/A | |
Active, not recruiting |
NCT02286687 -
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
|
Phase 2 |